烏磷布韋

烏磷布韋
臨床資料
商品名（英語：Drug nomenclature）	Uprifosbuvir
法律規範狀態
法律規範	美：研究性新藥;
識別資訊
	IUPAC命名法 propan-2-yl (2R)-2-[[[(2R,3R,4R,5R)-4-chloro-5-(2,4-dioxopyrimidin-1-yl)-3-hydroxy-4-methyloxolan-2-yl]methoxy-phenoxyphosphoryl]amino]propanoate; ;
CAS號	1496551-77-9
PubChem CID	90055716;
DrugBank	DB15206;
ChemSpider	57427403;
UNII	JW31KPS26S;
KEGG	D10996;
ChEMBL	ChEMBL3833371;
化學資訊
化學式	C22H29ClN3O9P
摩爾質量	545.9
3D模型（JSmol（英語：JSmol））	交互式圖像;
	SMILES C[C@H](C(=O)OC(C)C)N[P@@](=O)(OC[C@@H]1[C@H]([C@@]([C@@H](O1)N2C=CC(=O)NC2=O)(C)Cl)O)OC3=CC=CC=C3;
	InChI InChI=1S/C22H29ClN3O9P/c1-13(2)33-19(29)14(3)25-36(31,35-15-8-6-5-7-9-15)32-12-16-18(28)22(4,23)20(34-16)26-11-10-17(27)24-21(26)30/h5-11,13-14,16,18,20,28H,12H2,1-4H3,(H,25,31)(H,24,27,30)/t14-,16-,18-,20-,22-,36-/m1/s1; Key:SFPFZQKYPOWCSI-KHFYHRBSSA-N;

烏磷布韋（英語：Uprifosbuvir，MK-3682）是一種開發用於治療丙型肝炎的抗病毒藥物。它是一種核苷酸類似物，可用作NS5B RNA聚合酶抑制劑，目前處於III期人體臨床試驗中。^[1]^[2]^[3]

參考文獻

^ Soriano V, Fernandez-Montero JV, de Mendoza C, Benitez-Gutierrez L, Peña JM, Arias A, Barreiro P. Treatment of hepatitis C with new fixed dose combinations. Expert Opinion on Pharmacotherapy. August 2017, 18 (12): 1235–1242. PMID 28644739. doi:10.1080/14656566.2017.1346609.
^ Borgia G, Maraolo AE, Nappa S, Gentile I, Buonomo AR. NS5B polymerase inhibitors in phase II clinical trials for HCV infection. Expert Opinion on Investigational Drugs. March 2018, 27 (3): 243–250. PMID 29271672. doi:10.1080/13543784.2018.1420780.
^ Lawitz E, Gane E, Feld JJ, Buti M, Foster GR, Rabinovitz M, et al. Efficacy and safety of a two-drug direct-acting antiviral agent regimen ruzasvir 180 mg and uprifosbuvir 450 mg for 12 weeks in adults with chronic hepatitis C virus genotype 1, 2, 3, 4, 5 or 6. Journal of Viral Hepatitis. September 2019, 26 (9): 1127–1138. PMID 31108015. doi:10.1111/jvh.13132.